Phase I study of phenesterin (NSC-104469).
D000284:Administration, Oral; D000328:Adult; D000368:Aged; D000728:Androgens / Q000627:therapeutic use; D000970:Antineoplastic Agents / Q000009:adverse effects / Q000494:pharmacology* / Q000627:therapeutic use; D001772:Blood Cell Count; D001792:Blood Platelets; D001855:Bone Marrow Diseases / Q000139:chemically induced; D001943:Breast Neoplasms / Q000188:drug therapy*; D002699:Chlorambucil / Q000627:therapeutic use; D002776:Cholestanes / Q000009:adverse effects / Q000494:pharmacology* / Q000627:therapeutic use; D003520:Cyclophosphamide / Q000627:therapeutic use; D004967:Estrogens / Q000627:therapeutic use; D005472:Fluorouracil / Q000627:therapeutic use; D005938:Glucocorticoids / Q000627:therapeutic use; D006801:Humans; D007958:Leukocyte Count; D007970:Leukopenia / Q000139:chemically induced; D008727:Methotrexate / Q000627:therapeutic use; D008875:Middle Aged; D009588:Nitrogen Mustard Compounds / Q000009:adverse effects / Q000494:pharmacology* / Q000627:therapeutic use; D012632:Secosteroids / Q000009:adverse effects / Q000494:pharmacology / Q000627:therapeutic use; D013280:Stomatitis / Q000139:chemically induced; D013610:Tachycardia / Q000139:chemically induced; D013852:Thiotepa / Q000627:therapeutic use; D014750:Vincristine / Q000627:therapeutic use
D000728:Androgens; D000970:Antineoplastic Agents; D002776:Cholestanes; D004967:Estrogens; D005938:Glucocorticoids; D009588:Nitrogen Mustard Compounds; D012632:Secosteroids; D002699:Chlorambucil; D014750:Vincristine; D003520:Cyclophosphamide; D013852:Thiotepa; D005472:Fluorouracil; D008727:Methotrexate